MedTrace Logo

The Feasibility and Efficacy of a Two-week MCT Treatment of Anxiety Disorders in a Group Setting

NCT05402306 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-06-02

No results posted yet for this study

Summary

Long treatment durations may not always be feasible for patients due to pressure to get better quickly, long travel distance to treatment clinics, inflexible working hours, or childcare. To overcome these challenges intensive treatments are currently emerging and several research studies have shown significant and lasting results of diagnosis-specific intensive treatments. A transdiagnostic treatment in a group setting can contribute to a more efficient course of treatment for patients.

Research suggests that Metacognitive Therapy (MCT) is an effective treatment for anxiety disorders. However, MCT has not previously been used on inpatients over a two-week period. To make the treatment tangible for patients and easy to administer for therapists over a short time, attention training technique (ATT) will mainly be used as a changing technique.

The main aim of the study is to explore the feasibility and efficacy of intensive and short-term MCT for anxiety disorders in a group setting.

Conditions

  • Anxiety Disorders

Interventions

OTHER

Treatment group

Group metacognitive therapy, mainly with attention training technique over two weeks.

Sponsors & Collaborators

  • Modum Bad

    collaborator OTHER

  • University of Oslo

    lead OTHER

Principal Investigators

  • Sverre Urnes Johnson, PhD · University of Oslo & Modum Bad

  • Henrik Nordahl, PhD · Norwegian University of Science and Technology

  • KariAnne Vrabel, PhD · Modum bad & University of Oslo

  • Asle Hoffart, PhD · Modum Bad & University of Oslo

  • Therese R. Snuggerud, Masters · Modum Bad

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2023-01-28
Completion
2023-01-28

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05402306 on ClinicalTrials.gov